Ras inhibition induces insulin sensitivity and glucose uptake
Adi Mor, Elizabeta Aizman, Jacob George, Yoel Kloog, Adi Mor, Elizabeta Aizman, Jacob George, Yoel Kloog
Abstract
Background: Reduced glucose uptake due to insulin resistance is a pivotal mechanism in the pathogenesis of type 2 diabetes. It is also associated with increased inflammation. Ras inhibition downregulates inflammation in various experimental models. The aim of this study was to examine the effect of Ras inhibition on insulin sensitivity and glucose uptake, as well as its influence on type 2 diabetes development.
Methods and findings: The effect of Ras inhibition on glucose uptake was examined both in vitro and in vivo. Ras was inhibited in cells transfected with a dominant-negative form of Ras or by 5-fluoro-farnesylthiosalicylic acid (F-FTS), a small-molecule Ras inhibitor. The involvement of IκB and NF-κB in Ras-inhibited glucose uptake was investigated by immunoblotting. High fat (HF)-induced diabetic mice were treated with F-FTS to test the effect of Ras inhibition on induction of hyperglycemia. Each of the Ras-inhibitory modes resulted in increased glucose uptake, whether in insulin-resistant C2C12 myotubes in vitro or in HF-induced diabetic mice in vivo. Ras inhibition also caused increased IκB expression accompanied by decreased expression of NF-κB . In fat-induced diabetic mice treated daily with F-FTS, both the incidence of hyperglycemia and the levels of serum insulin were significantly decreased.
Conclusions: Inhibition of Ras apparently induces a state of heightened insulin sensitization both in vitro and in vivo. Ras inhibition should therefore be considered as an approach worth testing for the treatment of type 2 diabetes.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
- Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
- Jager J, Gremeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148:241–251.
- Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. Journal of Clinical Investigations. 1995;95:2409–2415.
- Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, et al. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. Journal of Biological Chemistry. 2006;281:7060–7067.
- Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389:610–614.
- Franckhauser S, Elias I, Rotter Sopasakis V, Ferre T, Nagaev I, et al. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia. 2008;51:1306–1316.
- Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11:191–198.
- Das UN. Obesity, metabolic syndrome X, and inflammation. Nutrition. 2002;18:430–432.
- Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes. 2002;51:2005–2011.
- Sinha S, Perdomo G, Brown NF, O'Doherty RM. Fatty acid-induced insulin resistance in L6 myotubes is prevented by inhibition of activation and nuclear localization of nuclear factor kappa B. Journal of Biological Chemistry. 2004;279:41294–41301.
- Jove M, Planavila A, Sanchez RM, Merlos M, Laguna JC, et al. Palmitate induces tumor necrosis factor-alpha expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-kappaB activation. Endocrinology. 2006;147:552–561.
- Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. Journal of Biological Chemistry. 2007;282:35279–35292.
- Bar Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103(2):227–238.
- Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993;366:643–654.
- Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227–238.
- Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689.
- Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev. 1998;8:49–54.
- McFall A, Ulku A, Lambert QT, Kusa A, Rogers-Graham K, et al. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. Mol Cell Biol. 2001;21:5488–5499.
- Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther. 2002;1:599–606.
- Philips MR. Compartmentalized signalling of Ras. Biochem Soc Trans. 2005;33:657–661.
- Rotblat B, Ehrlich M, Haklai R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467–489.
- George J, Afek A, Keren P, et al. Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation. 2002;105:2416–2422.
- Karusis D, Abramsky O, Grigoriadis N, Chapman J, Mizrachi-Koll R, et al. The Ras-pathway inhibitor S,trans-trans farnesythiosalicylic acid (FTS) suppresses experimental allergic encephalomyelitis. J Neuroimmunol. 2001. in press.
- Katsav A, Kloog Y, Korczyn AD, et al. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clin Exp Immunol. 2001;126:570–577.
- Katzav A, Kloog Y, Korczyn AD, Molina V, Blank M, et al. Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome. Immunobiology. 2003;207:47–50.
- Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol. 1999;9:601–604.
- Aharonson Z, Gana-Weisz M, Varsano T, Haklai R, Marciano D, et al. Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta. 1998;1406:40–50.
- Aizman E, Mor A, George J, Kloog Y. Ras inhibition attenuates pancreatic cell death and experimental type 1 diabetes: possible role of regulatory T cells. European Journal of Pharmacology. 2010;643:139–144.
- Mor A, Keren G, Kloog Y, George J. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. European Journal of Immunology. 2008;38:1493–1502.
- Mor A, Kloog Y, Keren G, George J. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice. European Journal of Pharmacology. 2009;616:301–305.
- Frost JA, Swantek JL, Stippec S, Yin MJ, Gaynor R, et al. Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. Journal of Biological Chemistry. 2000;275:19693–19699.
- Louzao MC, Espina B, Vieytes MR, Vega FV, Rubiolo JA, et al. "Fluorescent glycogen" formation with sensibility for in vivo and in vitro detection. Glycoconj J. 2008;25:503–510.
- Wang L, Liu Y, Yan Lu S, Nguyen KT, Schroer SA, et al. Deletion of Pten in Pancreatic {beta}-Cells Protects Against Deficient {beta}-Cell Mass and Function in Mouse Models of Type 2 Diabetes. Diabetes. 2010;59:3117–3126.
- Jove M, Planavila A, Laguna JC, Vazquez-Carrera M. Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kappaB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology. 2005;146:3087–3095.
- Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, et al. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism. 1995;44:645–651.
- Genot E, Cleverley S, Henning S, Cantrell D. Multiple p21ras effector pathways regulate nuclear factor of activated T cells. EMBO J. 1996;15:3923–3933.
- Genot E, Cantrell DA. Ras regulation and function in lymphocytes. Curr Opin Immunol. 2000;12:289–294.
- Karussis D, Abramsky O, Grigoriadis N, Chapman J, Mizrachi-Koll R, et al. The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis. J Neuroimmunol. 2001;120:1–9.
- Kloog Y, Cox AD. RAS inhibitors: potential for cancer therapeutics. Mol Med Today. 2000;6:398–402.
- DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194.
- Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96.
- Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11:183–190.
- Karin M, Takahashi T, Kapahi P, Delhase M, Chen Y, et al. Oxidative stress and gene expression: the AP-1 and NF-kappaB connections. Biofactors. 2001;15:87–89.
- Bjornholm M, Zierath JR. Insulin signal transduction in human skeletal muscle: identifying the defects in Type II diabetes. Biochemical Society Transactions. 2005;33:354–357.
- Shalom-Feuerstein R, Levy R, Makovski V, et al. Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. Biochim Biophys Acta. 2008;1783:985–993.
Source: PubMed